Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about RARE, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Triheptanoin FDA approved Jun 2020 · Dojolvi |
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) | Phase 3 · NCT05933200 | Active not recruiting |
| Vestronidase Alfa FDA approved Nov 2017 · Mepsevii |
MPS VII | N/A · NCT03775174 | Available |
| Aceneuramic Acid Extended-Release Tablets | Hereditary Inclusion Body Myopathy | Phase 3 · NCT02736188 | Terminated |
| Rebisufligene Etisparvovec | MPS IIIA | Phase 2/3 · NCT02716246 | Recruiting |
| Setrusumab | Osteogenesis Imperfecta | Phase 3 · NCT06636071 | Active not recruiting |
| Prophylactic Immunomodulatory (IM) Therapy | MPS IIIA | Phase 2/3 · NCT02716246 | Recruiting |
| Prednisolone | Glycogen Storage Disease Type IA | Phase 3 · NCT05139316 | Completed |
| Therapeutic Corticosteroid | OTC Deficiency | Phase 3 · NCT05345171 | Active not recruiting |
| Optimized Prophylactic IM Therapy | MPS IIIA | Phase 2/3 · NCT02716246 | Recruiting |
| Apazunersen | Angelman Syndrome | Phase 3 · NCT06617429 | Terminated |
| Biphosphonate | Osteogenesis Imperfecta | Phase 3 · NCT05768854 | Active not recruiting |
| Acetaminophen | Glycogen Storage Disease Type III | Phase 1/2 · NCT04990388 | Terminated |
| ABO-102 | MPS IIIA | Phase 1/2 · NCT04088734 | Terminated |
| UX053 | Glycogen Storage Disease Type III | Phase 1/2 · NCT04990388 | Terminated |
| UX016 | GNE Myopathy | Phase 1/2 · NCT07511556 | Recruiting |
| Triheptanoin oil | Huntington Disease | Phase 2 · NCT02453061 | Completed |
Also used in these trials (approved or third-party drugs, not RARE's own candidates): Sodium Acetate, Evinacumab, Adjuvant IM Therapy, Adjuvant Immunomodulatory (IM) Therapy, Zoledronic Acid, Burosumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
RARE holds $467M in cash and short-term investments (as of Sep 30, 2026) and burns about $70M/quarter from operations, an estimated runway of 20 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 8 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RARE files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Vanguard Portfolio Management | Institution (13G, 5%+) | 8,481,266 | 8.32% | 2026-09-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 8,141,384 | 7.99% | 2026-06-30 |
| RTW Investments, LP | Institution (13G, 5%+) | 7,796,895 | 7.65% | 2026-06-30 |
| STATE STREET CORPORATION | Institution (13G, 5%+) | 7,538,078 | 7.40% | 2026-09-30 |
| Madison Avenue International LP | 5%+ holder (13G) | 6,307,798 | 6.19% | 2026-10-13 |
| Vanguard Capital Management | Institution (13G, 5%+) | 5,058,419 | 4.96% | 2026-06-30 |
| Emil D Kakkis President & CEO, Director · +132,693 options |
Insider | 2,694,724 | 2.64% | 2026-04-16 |
| Dennis Karl Huang EVP, Chief Technical Operations Officer · +79,936 options |
Insider | 147,845 | 0.15% | 2026-04-16 |
| John Richard Pinion EVP, Chief Quality Operations Officer · +79,936 options |
Insider | 133,142 | 0.13% | 2026-04-16 |
| Erik Harris EVP & Chief Commercial Officer · +49,960 options |
Insider | 118,410 | 0.12% | 2026-04-16 |
| Eric Crombez EVP and Chief Medical Officer · +59,952 options |
Insider | 111,189 | 0.11% | 2026-05-05 |
| Karah Herdman Parschauer EVP and Chief Legal Officer · +49,960 options |
Insider | 92,562 | 0.09% | 2026-08-03 |
Share count 101,924,068 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-08-04 | FAYUVI | NDA | -25.3% | +3.2% | +7.1% |
| 2025-08-18 | — | BLA | +8.3% | +0% | +0.3% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RARE and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →